News
PCVX
--
0.00%
--
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 09/24 12:15
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)
Benzinga · 09/23 12:05
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
\- Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery -\- In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions -MENLO PARK, Calif. and GREENWICH
GlobeNewswire · 09/23 12:00
How To Avoid The Noise And Invest For Long-Term Success
Let's face it, today's retail investor is bombarded with information, and parsing through what is useful and what is not can be challenging.Avoiding noise and executing under pressure are critical to investing success.I've been managing custom-built equity portfolios since 2012, and hope to engage with those on Seeking Alpha interested in long-term investment success.I will look to do this with the tools I've developed to manage portfolios.
Seekingalpha · 09/21 16:16
We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 09/14 19:27
Vaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference
FOSTER CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide
GlobeNewswire · 09/09 22:28
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Data, Sorrento To Buy R&D Partner, Kymera IPO
  Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 20)
Benzinga · 08/21 11:43
The Daily Biotech Pulse: Poseida's Phase 1 Study Placed On Clinical Hold, Orphan Drug Designation For Krystal Biotech, Tiziana's Patent Award
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 12:21
Vaxcyte EPS misses by $0.45
Vaxcyte (PCVX): Q2 GAAP EPS of -$1.72 misses by $0.45.As of June 30, 2020, cash and equivalents were $410M vs. $59M as of December 31, 2019; driven by Vaxcyte’s IPO
Seekingalpha · 08/12 20:32
Vaxcyte EPS misses by $0.45
Vaxcyte (PCVX): Q2 GAAP EPS of -$1.72 misses by $0.45.As of June 30, 2020, cash and equivalents were $410M vs. $59M as of December 31, 2019; driven by Vaxcyte’s IPO
Seekingalpha · 08/12 20:32
Vaxcyte EPS misses by $0.45
Vaxcyte (PCVX): Q2 GAAP EPS of -$1.72 misses by $0.45.As of June 30, 2020, cash and equivalents were $410M vs. $59M as of December 31, 2019; driven by Vaxcyte’s IPO
Seekingalpha · 08/12 20:32
Vaxcyte EPS misses by $0.45
Vaxcyte (PCVX): Q2 GAAP EPS of -$1.72 misses by $0.45.As of June 30, 2020, cash and equivalents were $410M vs. $59M as of December 31, 2019; driven by Vaxcyte’s IPO
Seekingalpha · 08/12 20:32
Vaxcyte EPS misses by $0.45
Vaxcyte (PCVX): Q2 GAAP EPS of -$1.72 misses by $0.45.As of June 30, 2020, cash and equivalents were $410M vs. $59M as of December 31, 2019; driven by Vaxcyte’s IPO
Seekingalpha · 08/12 20:32
Vaxcyte EPS misses by $0.45
Vaxcyte (PCVX): Q2 GAAP EPS of -$1.72 misses by $0.45.As of June 30, 2020, cash and equivalents were $410M vs. $59M as of December 31, 2019; driven by Vaxcyte’s IPO
Seekingalpha · 08/12 20:32
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 08/11 12:20
The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. 
Benzinga · 07/06 12:56
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 06/18 12:34
Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
FOSTER CITY, Calif., June 16, 2020 -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines.
GlobeNewswire · 06/16 20:05
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16)
Benzinga · 06/16 12:15
Vaccine maker Vaxcyte's shares soar 22% in trading debut
Shares of Vaxcyte Inc. soared 22% in their trading debut Friday, after the company's IPO priced at the top end of its price range, and was upsized to 15.6 million shares from earlier plans to sell just 14 million. The company raised $249.6 million. The shares
MarketWatch · 06/12 15:24
Webull provides a variety of real-time PCVX stock news. You can receive the latest news about Vaxcyte, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PCVX
Vaxcyte Inc. is a vaccine company. The Company is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes pneumococcal conjugate vaccine (PCV) candidates. Its lead vaccine candidate is VAX-24, a 24-valent investigational PCV. Its pipeline also includes VAX-XP, VAX-A1 and VAX-PG. The Company's second PCV, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. VAX-PG is being developed as a protein vaccine for the treatment of periodontitis.
More